Submit a Manuscript: https://www.f6publishing.com

World J Gastrointest Surg 2024 May 27; 16(5): 1280-1290

ISSN 1948-9366 (online) DOI: 10.4240/wjgs.v16.i5.1280

ORIGINAL ARTICLE

Retrospective Cohort Study

Robotic vs laparoscopic abdominoperineal resection for rectal cancer: A propensity score matching cohort study and metaanalysis

Li Song, Wen-Qiong Xu, Zheng-Qiang Wei, Gang Tang

Specialty type: Gastroenterology and Hepatology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification

Scientific Quality: Grade B

Novelty: Grade A

Creativity or Innovation: Grade B Scientific Significance: Grade A

P-Reviewer: Vyshka G, Albania

Received: December 6, 2023 Revised: February 29, 2024 Accepted: April 10, 2024 Published online: May 27, 2024



Li Song, Department of Gastrointestinal Surgery, Chengdu Fifth People's Hospital, Chengdu 610000, Sichuan Province, China

Wen-Qiong Xu, Department of Nephrology, Chengdu Fifth People's Hospital, Chengdu 610000, Sichuan Province, China

Zheng-Qiang Wei, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400000, China

Gang Tang, Division of Biliary Tract Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

Corresponding author: Gang Tang, MD, Doctor, Division of Biliary Tract Surgery, Department of General Surgery, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu 610041, Sichuan Province, China. gangtang2017@163.com

Abstract

BACKGROUND

Robotic surgery (RS) is gaining popularity; however, evidence for abdominoperineal resection (APR) of rectal cancer (RC) is scarce.

AIM

To compare the efficacy of RS and laparoscopic surgery (LS) in APR for RC.

METHODS

We retrospectively identified patients with RC who underwent APR by RS or LS from April 2016 to June 2022. Data regarding short-term surgical outcomes were compared between the two groups. To reduce the effect of potential confounding factors, propensity score matching was used, with a 1:1 ratio between the RS and LS groups. A meta-analysis of seven trials was performed to compare the efficacy of robotic and laparoscopic APR for RC surgery.

RESULTS

Of 133 patients, after propensity score matching, there were 42 patients in each group. The postoperative complication rate was significantly lower in the RS group (17/42, 40.5%) than in the LS group (27/42, 64.3%) (P = 0.029). There was no significant difference in operative time (P = 0.564), intraoperative transfusion (P = 0.314), reoperation rate (P = 0.564) 0.314), lymph nodes harvested (P = 0.309), or circumferential resection margin (CRM) positive rate (P = 0.314) between the two groups. The meta-analysis showed patients in the RS group had fewer positive CRMs (P = 0.04), lesser estimated blood loss (P < 0.00001), shorter postoperative hospital stays (P = 0.02), and fewer postoperative complications (P = 0.002) than patients in the LS group.

CONCLUSION

Our study shows that RS is a safe and effective approach for APR in RC and offers better short-term outcomes than LS.

Key Words: Robotic surgery; Laparoscopic surgery; Abdominoperineal resection; Postoperative complications; Propensity

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This study compared the efficacy of robotic surgery (RS) and laparoscopic surgery (LS) in abdominoperineal resection (APR) for rectal cancer (RC). Our results showed that RS patients had fewer positive circumferential resection margins, less estimated blood loss, shorter postoperative hospital stays, and fewer postoperative complications than did LS patients. Our findings demonstrate that RS is a safe and effective approach for APR in RC and offers better short-term outcomes than LS. This study contributes to the existing evidence base and can assist surgeons and healthcare providers in making informed decisions on using RS in APR for RC.

Citation: Song L, Xu WQ, Wei ZQ, Tang G. Robotic vs laparoscopic abdominoperineal resection for rectal cancer: A propensity score matching cohort study and meta-analysis. World J Gastrointest Surg 2024; 16(5): 1280-1290

URL: https://www.wjgnet.com/1948-9366/full/v16/i5/1280.htm

DOI: https://dx.doi.org/10.4240/wjgs.v16.i5.1280

INTRODUCTION

Colorectal cancer is the third most common cancer and one of the most common causes of cancer-related deaths worldwide. Nearly 40% of colorectal cancers occur in the rectum[1]. Surgery is the primary treatment for rectal cancer (RC)[2]. Common surgical procedures for RC include intersphincteric resection, low anterior resection (LAR), anterior resection, and abdominoperineal resection (APR)[3]. APR, also known as Miles's procedure, was first reported by Miles [4] in 1908. With the increasing use of LAR for lower RC, the application of APR has gradually declined. However, APR remains the best choice for RC cases in lower locations, cases with perianal muscle invasion, or cases where sphincterpreserving techniques are unsuitable for radical resection[5].

Laparoscopic minimally invasive surgery for colorectal cancer was first reported in the 1990s[5]. Compared with traditional open surgery, laparoscopic surgery (LS) has been widely used in RC surgery due to its advantages of shorter hospital stays, reduced blood loss, and faster postoperative recovery [6,7]. However, some limitations of LS, such as a twodimensional field of view, amplification of operative tremors, and poor flexibility, may affect its efficacy in radical surgery [6,8]. These limitations are further amplified in the narrow pelvic cavity. However, robotic surgery (RS) offers a three-dimensional view, a stable camera platform, and flexible operating instruments [9]. The development of RS provides a potential approach that overcomes the limitations of LS. Several studies have compared the efficacy of laparoscopic and robotic APR for RC. However, the benefits of robotic APR remain controversial. Feng et al[10] showed that robotic APR significantly reduced the incidence of postoperative complications, rate of conversion to laparotomy, and length of hospital stay. However, some retrospective studies[11,12] have shown no significant difference in postoperative complication rates between robotic and laparoscopic APR.

Therefore, we conducted a retrospective cohort study to evaluate the effects of RS on postoperative complications, pathological findings, and postoperative recovery in RC patients undergoing APR. Propensity score matching (PSM) was performed to reduce the influence of imbalanced factors between the two groups. In addition, we performed a metaanalysis of all previous studies evaluating the efficacies of robotic and laparoscopic APR for RC surgery and combined the results of this trial.

MATERIALS AND METHODS

Study population

This retrospective study included 133 patients with pathologically confirmed RC who underwent APR via RS or LS at the First Affiliated Hospital of Chongqing Medical University from April 2016 to June 2022. This study was ethically ap-



proved by the Institutional Ethics Committee of the First Affiliated Hospital of Chongqing Medical University. All patients provided informed consent. Patients undergoing surgery for local recurrence after rectal resection, with malignant melanoma, younger than 18 years, or undergoing combined resection of other organs were excluded.

Patient demographics [age, sex, body mass index (BMI), the American Society of Anesthesiologists physical status classification (ASA) scores, comorbidity, tumor distance from the anal verge, and neoadjuvant therapy], surgical information (surgical approach, operative time, blood loss, and conversion to open surgery), postoperative outcomes [length of stay, reoperation, complications within 30 d, readmissions, mortality, time to first flatus, first defecation time, lymph nodes harvested, circumferential resection margin (CRM), and cost] were obtained from the electronic medical record system.

Surgical procedure

All laparoscopic and robotic procedures were performed by the same experienced surgeon. Robotic and laparoscopic approaches were used only for abdominal procedures. The perineal portion of the procedure was performed manually by the surgeon. All surgical procedures were performed in accordance with the principle of total mesorectal excision, which included resection of the entire mesorectum to the pelvic floor, ligation of the inferior mesenteric artery at the origin of the inferior mesenteric artery, and lymph node dissection. Perineal resection involved the removal of the internal and external anal sphincters and a part of the levator ani muscle. Extended resection of the levator ani muscle, posterior vaginal wall, and surrounding tissues was performed, if necessary, for tumor invasion. No procedure was taken to fill the pelvic cavity.

Primary and secondary endpoints

The primary endpoint was postoperative complications within 30 postoperative days. The secondary endpoints included operative time, blood loss, time to first flatus and defecation, conversion rate, intensive care rate, histological examination, morbidity, reoperation rate, transfusion rate, and length of hospital stay.

Statistical analysis

Data were presented as frequencies (percentages), means (standard deviation), or medians (interquartile range). Differences in categorical variables between the groups were examined by the Pearson χ^2 test. Meanwhile, differences in continuous variables between the two groups were analyzed using the Student's t-test or Mann-Whitney U test, as appropriate. PSM analysis based on patient demographics (male, age, BMI, neoadjuvant therapy, tumor location, and stage) and comorbidities (chronic obstructive pulmonary disease, hypertension, diabetes mellitus, coronary artery disease, and ASA) was performed to reduce potential confounders resulting from differences in baseline characteristics between the groups. The matching ratio was established as 1:1 using the nearest neighbor matching algorithm. Calipers were set to 0.05 times the standard deviation of the logarithm of the estimated propensity score. All statistical analyses were performed with IBM SPSS version 26. A P-value < 0.05 was considered statistically significant.

Meta-analysis

We conducted a meta-analysis of all published cohort studies, case-control studies, and randomized controlled trials (RCTs) following the PRISMA guidelines, comparing RS with LS in APR for RC. The PubMed, Embase, Web of Science, and Cochrane databases were searched from inception until December 7, 2022. Studies were included if they met the following criteria: (1) Patients undergoing APR for RC; (2) intervention with RS; (3) comparison with LS; (4) outcomes included postoperative complications, completeness of resection, operative time, length of hospital stay, mortality, conversion rate, lymph nodes harvested, and blood loss; and (5) cohort studies, case-control studies, or RCTs. The risk of bias in RCTs was assessed independently by two authors (Tang G and Song L) based on the Cochrane risk-of-bias tool. The quality of non-RCTs was assessed based on the Newcastle-Ottawa Scale. Data extracted from each eligible study were as follows: First author, year, country, study design, sample, age, sex, and outcomes. Heterogeneity between studies was assessed using the *I* statistic[13]. Mean differences (MD) or odds ratios (OR) across studies were combined using the random effects model[14]. One-study exclusion test was used to examine the impact of each study on the pooled effect size. Analyses were conducted using Review Manager (RevMan) Version 5.3 (The Nordic Cochrane Center, The Cochrane Collaboration 2014; Copenhagen, Denmark). A *P*-value < 0.05 was considered statistically significant.

RESULTS

Patient characteristics

In total, 133 patients (96 males and 37 females) who underwent APR for RC were included. The median (interquartile range: 25^{th} - 75^{th} percentile) age and mean BMI of the patients were 63.0 (55.5-70.0) years and $22.53 \pm 2.43 \text{ kg/m}^2$, respectively. Robotic APR was performed in 49 patients and laparoscopic APR in 84 patients. There were no significant differences in the ASA grade, sex, age, diabetes mellitus, chronic obstructive pulmonary disease, coronary artery disease, BMI, and tumor stage between the two groups. However, the proportion of patients with hypertension was higher in the RS group than in the LS group (P = 0.011).

Surgical results

After matching, 42 patients were included in each group (Table 1). Operative times were similar between the two groups

Table 1 Base	eline characteristic	s after propen	sity score mate	ching n (%)	
Table I Dase	fillic Gilalacteristic	o aitei piopeii	SILY SCOLE IIIAL	6111119, <i>11</i> (/0/	

	Group RS (<i>n</i> = 42)	Group LS (n = 42)	P value
Age (yr) ¹	63.5 (55-69)	65 (57.8-72.3)	0.211
Sex			1.000
Male	32 (76.2)	32 (76.2)	
Female	10 (23.8)	10 (23.8)	
BMI ²	22.5 (2.03)	22.6 (2.41)	0.815
COPD	8 (19)	8 (19)	1.000
Hypertension	11 (26.2)	9 (21.4)	0.608
Diabetes mellitus	2 (4.8)	4 (9.5)	0.397
Coronary artery disease	1 (2.4)	2 (4.8)	0.557
ASA Grade			0.890
1	5 (11.9)	4 (9.5)	
2	22 (52.4)	24 (57.1)	
3	15 (35.7)	14 (33.3)	
Neoadjuvant therapy received	9 (21.4)	8 (19)	0.786
Distance between tumor and AV (cm) ¹	3 (2-5)	3 (2.5-4)	0.996
Stage			0.969
I	10 (23.8)	10 (23.8)	
II	16 (38.1)	15 (35.7)	
Ш	16 (38.1)	17 (40.5)	

¹Values are median (interquartile range: 25th-75th percentile).

Values in parentheses are percentages, unless indicated otherwise. ASA: American Society of Anesthesiologists physical status classification; AV: Anal verge; BMI: Body mass index; COPD: Chronic obstructive pulmonary disease; RS: Robotic surgery; LS: Laparoscopic surgery.

(P = 0.564), with a median of 245 min for RS and 230 min for LS. The estimated blood loss was significantly lower in the RS group than in the LS group (P = 0.012). No significant differences in the rate of intraoperative blood transfusion were observed between the two groups (P = 0.314). In addition, there was no conversion to open surgery in either group

Postoperative complication rate was significantly lower in the RS group (17/42, 40.5%) than in the LS group (27/42, (64.3%) (P = 0.029). There were no significant differences observed in pneumonia (P = 1.000), urinary infection rate (P = 1.000). 0.557), ileus rate (P = 1.000), wound infection rate (P = 0.057), abdominal infection rate (P = 0.365), reoperation rate (P = 0.365) 0.314), urinary retention (P = 0.557), or intensive care rate (P = 0.152) between the two groups, and no deaths were recorded in both groups. There was no significant difference between the two groups in the number of examined lymph nodes (P = 0.309) and CRM positive rate (P = 0.314). Median hospitalization costs were significantly higher in the RS group (81886.5 RMB) than in the LS group (70102.8 RMB; P = 0.040).

Regarding intestinal function recovery, the time to first flatus in the robotic group (P = 0.023) was significantly shorter than that in the laparoscopic group. However, there was no significant difference in the time to first defecation between the two groups (P = 0.679). In addition, the median postoperative hospital stay was significantly shorter in the RS group (9.0 d) than in the LS group (11.0 d; P = 0.044).

Meta-analysis

Our literature search yielded 810 potential records, of which 11 published articles were completely reviewed. In addition to our study, six trials[10-12,15-17] published between 2015 and 2022 were included. Details of the seven eligible trials are summarized in Table 3. The risk of bias was low in all seven studies included in the review.

Meta-analysis of the six studies[10-12,16,17] showed no significant difference in operative time [MD = 17.86 min; 95%CI: -2.33 to 38.05; P = 0.08, with high heterogeneity (P = 75%)] (Figure 1A and Table 4). Intraoperative blood loss was significantly lower in the RS group than in the LS group (MD -26.36 mL, 95%CI: -32.02 to -20.70; I^2 = 0%, P = 0.47) (Figure 1B). A total of 6290 participants in the seven studies [10-12,15-17] had postoperative complications. The incidence of postoperative complications was lower in the RS group than in the LS group (OR 0.69, 95% CI: 0.55-0.88; $I^2 = 14\%$, P = 14%, 0.32) (Figure 1C). There was no significant difference (OR, 0.71; 95%CI: 0.26-1.94; P = 0.50) in the postoperative mortality between the RS and LS groups, with low heterogeneity between studies ($I^2 = 0\%$, P = 0.60) (Figure 1D). Data on reope-

Table 2 Operative out	compe and poetoporat	ive complication of	tor proponeity eco	ro matching n (%)
Table 2 Oberative out	comes and postoberal	ive comblication at	ter brobensity sco	re matching, n (%)

	Group RS (n = 42)	Group LS (n = 42)	P value
Duration of surgery (min) ¹	245 (191.5-295)	230 (200-286.3)	0.564
Intraoperative blood loss (ml) ¹	60 (50-100)	100 (50-200)	0.012
Transfusion	1 (2.4)	0 (0)	0.314
Days to first flatus ¹	2 (1-2)	2 (2-3)	0.023
Days to first defecation ¹	3 (2.8-4.3)	3 (2.8-4.3)	0.679
Reoperation	0 (0)	1 (2.4)	0.314
Mortality	0 (0)	0 (0)	-
Intensive care	0 (0)	2 (4.8)	0.152
Conventional open	0 (0)	0 (0)	-
Circumferential resection margin positive	0 (0)	1 (2.4)	0.314
Lymph nodes harvested ¹	15 (11-18)	13 (9-18.3)	0.309
Perineural invasion	1 (2.4)	1 (2.4)	1.000
Lymphovascular invasion	2 (4.8)	2 (4.8)	1.000
Hospital stay (d) ¹	9 (7.8-13)	11 (8-18)	0.044
Postoperative complications	17 (40.5)	27 (64.3)	0.029
Urinary infection	2 (4.8)	1 (2.4)	0.557
Pneumonia	1 (2.4)	1 (2.4)	1.000
Ileus	3 (7.1)	3 (7.1)	1.000
Wound infection	5 (11.9)	12 (28.6)	0.057
Intraabdominal infection	5 (11.9)	8 (19)	0.365
Urinary retention	1 (2.4)	2 (4.8)	0.557
Hospital charge (RMB) ¹	81886.5 (70540.5-109854.2)	70102.8 (60308.6-109415.4)	0.040

¹Values are median (interquartile range: 25th-75th percentile).

Values in parentheses are percentages, unless indicated otherwise. RS: Robotic surgery; LS: Laparoscopic surgery.

ration rates were reported in four studies [10,12,17]. The RS and LS groups were comparable in terms of reoperation rate (OR, 0.40; 95%CI: 0.16-1.03; P = 0.06; P = 0.06) (Figure 1E). Furthermore, no significant differences were observed between RS and LS in terms of conversion to open surgery (OR, 0.45; 95%CI: 0.07-2.89; P = 0.40; $I^2 = 54\%$), estimated at 1.8% for RS and 5.0% for LS (Figure 1F). The overall effect of the seven studies[10-12,15-17] reporting the length of stay showed that RS was associated with reduced length of hospital stay (MD -1.51 d; 95%CI: -2.80 to -0.21), with significant heterogeneity (P = 89%, P < 0.00001) between studies (Figure 1G). Five studies [10-12,16] described the number of lymph nodes harvested, and there was no significant difference in the number of lymph nodes harvested between the RS and LS groups, with low heterogeneity (MD, 0.33; 95%CI: -1.03 to 1.69; P = 0.64; $I^2 = 14\%$) (Figure 1H). Data on CRM positive rates were reported in five studies[10-12,16]. Surgery with the robotic-assisted technique for APR reduced the CRM positive rate (OR, 0.39; 95%CI: 0.16-0.95; P = 0.04; $I^2 = 0\%$) (Figure 1I).

The results of the sensitivity analysis showed that the total effect size of intraoperative blood loss, postoperative complications, postoperative mortality, reoperation rate, conversion to open surgery, and number of lymph nodes harvested was not affected by the elimination of any one study. However, the total effect size for operative time changed (MD, 24.05 min; 95%CI: 3.71-44.40; $I^2 = 0\%$, P = 0.47) when the study by Kasai *et al*[11] was excluded. Sensitivity analysis indicated that studies by Gorgun et al[12] (OR, 0.41; 95%CI: 0.16-1.06; $I^2 = 0\%$, P = 0.96) and Feng et al[10] (OR, 0.38; 95%CI: 0.08-1.84; $I^2 = 0\%$, P = 0.94) and the present study (OR, 0.40; 95%CI: 0.16-1.00; $I^2 = 0\%$, P = 0.94) prominently affected the total effect size of the CRM positive rate. The total effect size of the length of hospital stay was changed by the exclusion of the study by Kasai et al [11] (MD, -1.27 d; 95%CI: -2.59 to 0.05), the present study (MD, -1.24 d; 95%CI: -2.60 to 0.12), and the study by Feng et al[10] (MD, -1.28 d; 95%CI: -2.68 to 0.12).

Table 2.0	la a una ada ula di a a	of tale lands	al and the Alexander	An amaluata
lable 3 C	haracteristics	of trials inclu	aea in the me	eta-anaivsis

Ref.	Country	Study design	Sample	Age	Gender (M/ F)	Outcomes	NOS
Moghadamyeghaneh et al[15], 2015	United States	Retrospective cohort study	R: 872; L: 4737	R: 64; L: 62	R: 556/316; L: 2844/1893	Hospital stay, postoperative complications, mortality	7
Kamali <i>et al</i> [16], 2017	United Kingdom	Retrospective case-control study	R: 11; L: 11	R: 71; L: 57	R: 7/4; L: 9/2	Postoperative complications, mortality, CRM, operating time, hospital stay, lymph nodes harvested, conversion rate	8
Gavrila et al[17], 2021	Romania	Retrospective case-control study	R: 46; L: 63	R: 62; L: 62	R: 34/12; L: 32/31	Postoperative complications, mortality, operating time, blood loss, hospital stay, conversion rate, reoperation rate	8
Kasai <i>et al</i> [11], 2022	Japan	Retrospective cohort study	R: 33; L: 20	R: 74; L: 78	R: 20/13; L: 16/4	Postoperative complications, CRM, operating time, blood loss, hospital stay, conversion rate, lymph nodes harvested	8
Feng <i>et al</i> [10], 2022	China	Randomized controlled trial	R: 174; L: 173	R: 58; L: 60	R: 108/66; L: 113/60	Postoperative complications, mortality, CRM, operating time, blood loss, hospital stay, conversion rate, reoperation rate, lymph nodes harvested	-
Gorgun <i>et al</i> [12], 2022	United States	Retrospective PSM	R: 34; L: 34	R: 66; L: 66	R: 25/9; L: 25/9	Postoperative complications, CRM, operating time, blood loss, hospital stay, conversion rate, reoperation rate, lymph nodes harvested	9
Current study, 2022	China	Retrospective PSM	R: 34; L: 34	R: 34; L: 34	R: 34; L: 34	Lymph nodes harvested, postoperative complications, mortality, CRM, operating time, blood loss, hospital stay, conversion rate, reoperation rate	9

 $CRM: Circumferential\ resection\ margin; F: Female; L:\ Laparoscopic\ abdominoperineal\ resection; M:\ Male; NOS:\ Newcastle-Ottawa\ Scale; PSM:\ Propensity$ score matching; R: Robotic abdominoperineal resection.

Table 4 Summary of results from all outcomes	5				
Indicators	No. of studies	Events for RS	Events for LS	Effect size	95%CI
Operative time	6	-	-	17.86 min	-2.33, 38.05
Intraoperative blood loss	5	-	-	-26.36 mL	-32.02, -20.70
Postoperative complications	7	315/1211	1651/5079	0.69	0.55, 0.88
Postoperative mortality	5	4/1144	29/5025	0.71	0.26, 1.94
Reoperation	4	5/296	15/312	0.40	0.16, 1.03
Conversion to open surgery	6	6/339	17/342	0.45	0.07, 2.89
The length of stay	7	-	-	-1.51 d	-2.80, -0.21
Lymph nodes harvested	5	-	-	0.33	-1.03, 1.69
Circumferential resection margin positive	5	7/294	17/280	0.39	0.16, 0.95

RS: Robotic surgery; LS: Laparoscopic surgery.

DISCUSSION

With advancements in technology, LS is gradually becoming the preferred technique for colorectal surgery. LS is safe and effective in the short and long term[9]. However, laparoscopic RC surgery has some inherent limitations, especially in patients with low RC[18]. In addition, neoadjuvant use can lead to pelvic tissue fibrosis, which increases the difficulty of surgery and affects the efficacy of LS[9]. RS is another surgical technique that is under development. Compared with LS, RS has several major advantages, including a wider surgical field, more flexible surgical instruments, and less fatigue for doctors[19]. In addition, LS is difficult to perform on the pelvic floor and requires a long learning curve, whereas RS has a shorter learning period, making this technique easier for younger doctors to learn[20,21]. A recently published metaanalysis[21] showed that robotic rectal surgery had similar long-term outcomes as LS, with shorter operative time, lower incidence of postoperative complications, shorter hospital stays, and lower conversion to open surgery rates. However, there are few related studies on RS for APR, and the efficacy is still controversial. Postoperative complications of minimally invasive surgery for RC are as high as 27%[3]. In addition, the incidence of postoperative complications was higher

A	Rob	otic		Lapa	rosco	pic		Mean difference	Mean d	lifference
	Mean		otal	Mean			Weight	IV, random, 95%CI		m, 95%CI
2017, Kamali	327	34	11	251	55	11		76.00 [37.79, 114.21]		·
2021, Gavrila	221	42	46	191	38	63				_
·	77.59 8			307.44		20		-29.85 [-74.01, 14.31]		
•		3.22	42	246.14	80.44	42				
2022, Feng 2	06.76 1	8.69	174	197.81	58.31	173	26.2%	8.95 [-0.17, 18.07]		
2022, Gorgun	319	132	34	308	139	34	7.3%	11.00 [-53.43, 75.43]		
T. (. 1 (0.70) 0.10						- 40	400.001	4-00-00-00-00-0		
Total (95% CI)	0.00 01"		340	.	0.004		100.0%	17.86 [-2.33, 38.05]		
Heterogeneity: Tau² = 382 Test for overall effect: Z =				= 5 (P =	0.001);	* = /:	0%	-10	0 -50	
rest for overall effect; Z =	= 1.73 (P	= 0.06)						10	Favours [Laparoscopic]	
									. avoaro [zaparoscopie]	. 4.04.0 [0504.0]
	Rob				roscop			Mean difference		lifference
Study or subgroup M	lean	SD To	otal N	1ean	SD	Total	Weigh	IV, random, 95%C	IV, rando	m, 95%CI
2021, Gavrila	150	50	46	170	50	63	8.9%	-20.00 [-39.01, -0.99]		1
2021, Kasai 99	9.12 120	.72	33 1	10.04	126.86	20	0.7%	-10.92 [-80.11, 58.27]		
		.68			152.86	42		-68.68 [-117.48, -19.88]		
. •			174 1		37.38	173		-26.49 [-32.49, -20.49]		
2022, Gorgun	324	316	34	333	381	34	0.1%	-9.00 [-175.38, 157.38]		
Total (95% CI)			329			332	100.0%	-26.36 [-32.02, -20.70]	•	
Heterogeneity: Tau² = 0.00	0: Chi² =			= 0.47): I² = 0º		1001070	20.00 [02.02, 20.10]	' 	+ + +
Test for overall effect: Z =			•		,,			-2	-100	0 100 200
	•		,						Favours [Robotic]	Favours [Laparoscopic]
									0.11	
		Robot		•	roscop			Odds ratio		ratio
Study or subgroup	Ev	ents	Total	Event	s To	tal V	/eight I	4-H, random, 95%CI	M-H, rando	om, 95%CI
2015, Moghadamyeghan	neh	235	872	153	7 4	737	59.9%	0.77 [0.65, 0.90]		
2017, Kamali		5	10		4	10	1.8%	1.50 [0.26, 8.82]		 •
2021, Gavrila		13	46	1	8	63	7.3%	0.98 [0.42, 2.29]		
2021, Kasai		9	33	1	0	20	4.0%	0.38 [0.12, 1.20]		†
2022, Current study		17	42	2	27	42	6.7%	0.38 [0.16, 0.91]		
2022, Feng		23	174			173	14.8%	0.49 [0.28, 0.86]		
2022, Gorgun		13	34	1	4	34	5.6%	0.88 [0.33, 2.34]		
F-4-1 (0FN/ OD			4044				00.00/	0.00 [0.55 0.00]	_	
Fotal (95% CI)		045	1211	407		J/9 1	00.0%	0.69 [0.55, 0.88]	•	
Total events Heterogeneity: Tau² = 0.0	02. Chi2.	315	-df - C	165		- 440/		F		
Test for overall effect: Z				(P - U	32), 1	- 1470				1 10 10
	y 25.0	' = 0.00	02)					0.0		Favours [Laparoscopic]
)		? = 0.00 Robot		Lapa	roscop	ic		Odds ratio	Favours [Robotic]	
		Robot	tic	Lapa Event			/eight /		Favours [Robotic] Odds	Favours [Laparoscopic]
Study or subgroup	Ev	Robot rents	tic Total	Even	ts To	tal V		Odds ratio 4-H, random, 95%CI	Favours [Robotic] Odds	Favours [Laparoscopic]
Study or subgroup 2015, Moghadamyeghan	Ev	Robot vents	tic Total 872	Event 2	ts To	tal V 737	90.9%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22]	Favours [Robotic] Odds	Favours [Laparoscopic]
Study or subgroup 2015, Moghadamyeghan 2017, Kamali	Ev	Robot vents	tic Total 872 10	Even:	ts To	737 10		Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33]	Favours [Robotic] Odds	Favours [Laparoscopic]
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila	Ev	Robot vents 4 0 0	872 10 46	Even:	ts To	737 10 63	90.9%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable	Favours [Robotic] Odds	Favours [Laparoscopic]
2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study	Ev	Robot vents	tic Total 872 10	Even:	ts To	737 10	90.9%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33]	Favours [Robotic] Odds	Favours [Laparoscopic]
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study	Ev	Robot vents 4 0 0	872 10 46 42	Even:	ts To	737 10 63 42	90.9%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable	Favours [Robotic] Odds	Favours [Laparoscopic]
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng	Ev	Robot vents 4 0 0	872 10 46 42	Even:	8 47 0 0 0 0	737 10 63 42 173	90.9%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable	Favours [Robotic] Odds	Favours [Laparoscopic]
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI)	Ev	Robot vents 4 0 0 0 0	872 10 46 42 174	Event 2	8 41 1 0 0 0 0 50	737 10 63 42 173	90.9% 9.1%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable	Favours [Robotic] Odds	Favours [Laparoscopic]
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0	Evneh	Robot yents 4 0 0 0 0 0 4 = 0.28,	872 10 46 42 174 1144 df = 1	Event 2	8 41 1 0 0 0 0 50	737 10 63 42 173	90.9% 9.1%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable	Favours [Robotic] Odds M-H, rando	Favours [Laparoscopic] ratio om, 95%CI
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0	Evneh	Robot yents 4 0 0 0 0 0 4 = 0.28,	872 10 46 42 174 1144 df = 1	Event 2	8 41 1 0 0 0 0 50	737 10 63 42 173	90.9% 9.1%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable	Favours [Robotic] Odds M-H, rando	Favours [Laparoscopic] ratio bm, 95%CI 1 5 20
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0	Evneh	Robot yents 4 0 0 0 0 0 4 = 0.28,	872 10 46 42 174 1144 df = 1	Event 2	8 41 1 0 0 0 0 50	737 10 63 42 173	90.9% 9.1%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable	Favours [Robotic] Odds M-H, rando	Favours [Laparoscopic] ratio om, 95%CI
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0	Evneh 00; Chi² = 0.67 (P	4 0 0 0 0 0 4 = 0.28,	872 10 46 42 174 1144 df = 1	2 (P = 0.	28 47 1 0 0 0 0 50 9 60); ² =	737 10 63 42 173	90.9% 9.1%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94]	Favours [Robotic] Odds M-H, rando 0.05 0.2 Favours [Robotic]	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic]
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.6 Fest for overall effect: Z	Evneh 00; Chi ² : = 0.67 (<i>P</i>	4 0 0 0 0 4 = 0.28, 2 = 0.50	872 10 46 42 174 1144 df = 1	Event 2 $(P = 0.000)$	ts To 8 47 1 0 0 0 0 50 9 60); ² =	737 10 63 42 173 025 1	90.9% 9.1% 00.0%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94]	Favours [Robotic] Odds M-H, rando 0.05 0.2 Favours [Robotic] Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0 Fest for overall effect: Z =	Evneh 00; Chi²: = 0.67 (P Robo	Robot vents 4 0 0 0 0 0 4 = 0.28, v = 0.50	872 10 46 42 174 1144 df = 1	Event 2 (P = 0.	ts To 8 4: 1 0 0 0 0 0 50 9 60); ² =	737 10 63 42 173 025 1 Wei	90.9% 9.1% 9.00.0%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI	Favours [Robotic] Odds M-H, rando 0.05 0.2 Favours [Robotic]	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.6 Fest for overall effect: Z =	Evneh 00; Chi ² : = 0.67 (P Robo Events	Robot vents 4 0 0 0 0 0 4 = 0.28, v = 0.50	872 10 46 42 174 1144 df = 1 10) Lapul Eve	Event $\frac{2}{2}$ $(P = 0)$ paroscents $\frac{2}{2}$	ts To 88 4: 1 0 0 0 50 9 60); ² =	737 10 63 42 173 025 1 Weig 9.	90.9% 9.1% 9.00.0% 9.1%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64]	Favours [Robotic] Odds M-H, rando 0.05 0.2 Favours [Robotic] Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio
2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0 Fest for overall effect: Z =	Evneh 00; Chi²: = 0.67 (β Robo Events 0 0	Robot vents 4 0 0 0 0 0 4 = 0.28, v = 0.50 otic Tota	872 10 46 42 174 1144 df = 1 Lappil Leve	Event 2 $(P = 0.00)$ paroscents 2 1	ts To 18 4: 1 0 0 0 50: 19 60); ² = 10 copic Total 63 42	737 10 63 42 173 225 1 Wei	90.9% 9.1% 9.00.0% 9ht M-33% 44%	Odds ratio 1-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22]	Favours [Robotic] Odds M-H, rando 0.05 0.2 Favours [Robotic] Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio
2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.1 Fest for overall effect: Z = Study or subgroup 2021, Gavrila 2022, Current study 2022, Feng	00; Chi ² := 0.67 (<i>P</i> Robc Events 0 0 5	Roboti vents 4 0 0 0 0 0 4 4 = 0.28, 0 = 0.50 Tota 44, 174	872 10 46 42 174 1144 df = 1 Lappil Leve	2 (P = 0.0 cents 2 1 10	28 47 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	vtal V 737 10 63 42 173 225 1 € 0% Weig 9. 8. 73.	90.9% 9.1% 00.0% ght M- 3% 4% 0%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44]	Favours [Robotic] Odds M-H, rando 0.05 0.2 Favours [Robotic] Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0 Fest for overall effect: Z = 0.0 Study or subgroup 2021, Gavrila 2022, Current study 2022, Feng	Evneh 00; Chi²: = 0.67 (β Robo Events 0 0	Roboti vents 4 0 0 0 0 0 4 4 = 0.28, 0 = 0.50 Tota 44, 174	872 10 46 42 174 1144 df = 1 Lappil Leve	Event 2 $(P = 0.00)$ paroscents 2 1	ts To 18 4: 1 0 0 0 50: 19 60); ² = 10 copic Total 63 42	vtal V 737 10 63 42 173 225 1 € 0% Weig 9. 8. 73.	90.9% 9.1% 9.00.0% 9ht M-33% 44%	Odds ratio 1-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22]	Favours [Robotic] Odds M-H, rando 0.05 0.2 Favours [Robotic] Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio
2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0 Fest for overall effect: Z : Study or subgroup 2021, Gavrila 2022, Current study 2022, Feng 2022, Gorgun	00; Chi ² := 0.67 (<i>P</i> Robc Events 0 0 5	4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	872 10 46 42 174 1144 df = 1 Lap	2 (P = 0.0 paroscents 2 1 10	es To 88 47 1 0 0 0 0 50 9 60); 2 = opic Total 63 42 173 34	otal V 737 10 63 42 173 025 1 € 0% Weig 9. 8. 73. 9.	90.9% 9.1% 00.0% ght M- 33% 44% 00% 33%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07]	Favours [Robotic] Odds M-H, rando 0.05 0.2 Favours [Robotic] Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.1 Fest for overall effect: Z : Study or subgroup 2021, Gavrila 2022, Current study 2022, Feng 2022, Gorgun Fotal (95% CI)	00; Chi ² = 0.67 (P Robo Events 0 0 0 0	Roboti 4 0 0 0 0 4 4 0 0 5 7 1 7 1 1 7 1 7 1 7 1 7 1 7 1 7 1 7 1	872 10 46 42 174 1144 df = 1 Lap	2 (P = 0.0 aroscents 2 1 10 2 2	es To 88 47 1 0 0 0 0 50 9 60); 2 = opic Total 63 42 173 34	vtal V 737 10 63 42 173 225 1 € 0% Weig 9. 8. 73.	90.9% 9.1% 00.0% ght M- 33% 44% 00% 33%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44]	Favours [Robotic] Odds M-H, rando 0.05 0.2 Favours [Robotic] Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.6 Fest for overall effect: Z : Study or subgroup 2021, Gavrila 2022, Current study 2022, Feng 2022, Gorgun Fotal (95% CI) Fotal events	00; Chi²: = 0.67 (P Robo Events 0 0 5 0	Roboti 4 0 0 0 0 4 4 = 0.28, 2 = 0.500 Tota 46 47 174 34	872 10 46 42 174 1144 df = 1 114 Eve	2 (P = 0.0 arosc 2 1 10 2 15	es To 8 4 1 0 0 0 0 0 50 99 60); ² = copic Total 63 42 173 34 312	9. 100.	90.9% 9.1% 00.0% 9ht M- 3% 4% 0% 3%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07]	Favours [Robotic] Odds M-H, rando 0.05 0.2 Favours [Robotic] Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio
2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0 Est for overall effect: Z = 0.0 Est for overall effect: Z = 0.0 Estudy or subgroup 2021, Gavrila 2022, Current study 2022, Feng 2022, Gorgun Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0	00; Chi²: = 0.67 (P Robo Events 0 0 5 0.00; Chi	Roboti 4 0 0 0 0 4 4 = 0.28, 2 = 0.500 Tota 44, 47, 34 296	1144	2 (P = 0.0 arosc 2 1 10 2 15	es To 8 4 1 0 0 0 0 0 50 99 60); ² = copic Total 63 42 173 34 312	9. 100.	90.9% 9.1% 00.0% 9ht M- 3% 4% 0% 3%	Odds ratio 1-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07] 0.40 [0.16, 1.03]	Favours [Robotic] Odds M-H, rando 0.05 0.2 Favours [Robotic] Odds M-H, rando	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio om, 95%CI
2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0 Est for overall effect: Z = 0.0 Est for overall effect: Z = 0.0 Estudy or subgroup 2021, Gavrila 2022, Current study 2022, Feng 2022, Gorgun Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0	00; Chi²: = 0.67 (P Robo Events 0 0 5 0.00; Chi	Roboti 4 0 0 0 0 4 4 = 0.28, 2 = 0.500 Tota 44, 47, 34 296	1144	2 (P = 0.0 arosc 2 1 10 2 15	es To 8 4 1 0 0 0 0 0 50 99 60); ² = copic Total 63 42 173 34 312	9. 100.	90.9% 9.1% 00.0% 9ht M- 3% 4% 0% 3%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07]	Favours [Robotic] Odds M-H, rando 0.05 0.2 Favours [Robotic] Odds M-H, rando 0.1 1	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio om, 95%CI
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0 Study or subgroup 2021, Gavrila 2022, Current study 2022, Feng 2022, Gergun Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0	00; Chi²: = 0.67 (P Robo Events 0 0 5 0.00; Chi	Roboti 4 0 0 0 0 4 4 = 0.28, 2 = 0.500 Tota 44, 47, 34 296	1144	2 (P = 0.0 arosc 2 1 10 2 15	es To 8 4 1 0 0 0 0 0 50 99 60); ² = copic Total 63 42 173 34 312	9. 100.	90.9% 9.1% 00.0% 9ht M- 3% 4% 0% 3%	Odds ratio 1-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07] 0.40 [0.16, 1.03]	Favours [Robotic] Odds M-H, rando 0.05 0.2 Favours [Robotic] Odds M-H, rando 0.1 1	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio om, 95%CI
2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0 Est for overall effect: Z = 0.0 Est for overall effect: Z = 0.0 Estudy or subgroup 2021, Gavrila 2022, Current study 2022, Feng 2022, Gorgun Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0	00; Chi²: = 0.67 (P Robo Events 0 0 5 0.00; Chi	Roboti 4 0 0 0 0 4 4 0 0 5 Tota 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	1144 1144	2 (P = 0.0 arosc 2 1 10 2 15	es To 1 1 0 0 0 0 50 9 60); 2 = Total 63 42 173 34 312 = 0.93);	9. 100.	90.9% 9.1% 00.0% 9ht M- 3% 4% 0% 3%	Odds ratio 1-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07] 0.40 [0.16, 1.03]	Favours [Robotic] Odds M-H, rando 0.05 0.2 Favours [Robotic] Odds M-H, rando 0.1 1	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio om, 95%CI
2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal eyents Heterogeneity: Tau² = 0.6 Fest for overall effect: Z = 0.0 5021, Gavrila 2022, Current study 2022, Gorgun Fotal (95% CI) Fotal eyents Heterogeneity: Tau² = 0.0 Fotal (95% CI) Fotal eyents Heterogeneity: Tau² = 0.0 Fest for overall effect: Z	00; Chi ² := 0.67 (P Robo Events 0 0 5 0.00; Chi Z = 1.90	Roboti 4 0 0 0 0 4 4 = 0.28, 2 = 0.50 tic Tota 46 47 17 3 296 (P = 0.40)	1144	Event 2 $(P = 0.0)$ $(P = 0.0$	es To 8 4 1 1 0 0 0 0 50 9 60); 2 = opic Total 63 42 173 34 312 = 0.93);	weight weight with the second	90.9% 9.1% 00.0% 9.1% 00.0% 9.1% 00.0%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07] 0.40 [0.16, 1.03]	Odds M-H, rando 0.05 0.2 Favours [Robotic] Odds M-H, rando 0.1 1 Favours [Robotic]	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio om, 95%CI
2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.1 Fest for overall effect: Z : Study or subgroup 2021, Gavrila 2022, Current study 2022, Feng 2022, Gorgun Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0 Fotal (95% CI) Fotal events Fotal events Fotal for overall effect: Z	00; Chi ² = 0.67 (P Robo Events 0 5 0.00; Chi 2 1.90 Robo Events	## Roboti	1144	2 (P = 0.0 arosc ents 2 1 10 2 15 = 3 (P = 0.0 arosc ents 2 1 10 2 15 = 3 (P = 0.0 arosc ents 2 1 10 2 15 = 3 (P = 0.0 arosc ents 2 1 10 2 15 = 3 (P = 0.0 arosc ents 2 1 10 2 15 = 3 (P = 0.0 arosc ents 2 1 10 2 10 10 10 10 10 10 10 10 10 10 10 10 10	es To 8 47 1 0 0 0 0 0 50 9 60); 2 = opic Total 63 42 173 34 312 = 0.93);	weight with the second	90.9% 9.1% 00.0% ght M- 3% 4% 0% 3% 0% %	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07] 0.40 [0.16, 1.03]	Odds M-H, rando O.05 0.2 Favours [Robotic] Odds M-H, rando Odds M-H, rando Otds M-H, rando Otds M-H, rando Odds M-H, rando Odds Odds Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio om, 95%CI
2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Fest for overall effect: Z Study or subgroup 2021, Gavrila 2022, Current study 2022, Feng 2022, Current study 2022, Feng 2022, Gorgun Fotal (95% CI) Fotal events Fleterogeneity: Tau² = 0 Fotal (95% CI) Fotal events Fleterogeneity: Tau² = 0 Fest for overall effect: Z	00; Chi ² = 0.67 (P Robo Events 0 0 5 0.00; Chi Z = 1.90 Robo Events 1	Roboti 4 0 0 0 0 4 4 = 0.28, 2 = 0.50	1144 114 1144 1	2 (P = 0.0 arosc ents 2 1 10 2 15 = 3 (P = 0.0 arosc ents 0 10 2 15 = 3 (P	es To 8 4 1 1 0 0 0 0 50 9 60); 2 = opic Total 63 42 173 34 312 = 0.93); opic Total	weight weight 18.	90.9% 9.1% 00.0% ght M- 3% 4% 0% 3% 0% 3% 0% 4%	Odds ratio 1-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07] 0.40 [0.16, 1.03] Odds ratio H, random, 95%CI 3.32 [0.12, 91.60]	Odds M-H, rando O.05 0.2 Favours [Robotic] Odds M-H, rando Odds M-H, rando Otds M-H, rando Otds M-H, rando Odds M-H, rando Odds Odds Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio om, 95%CI
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0 Study or subgroup 2021, Gavrila 2022, Current study 2022, Feng 2022, Gorgun Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0 Fotal (95% CI) Fotal events Fotal (95% CI)	00; Chi ² = 0.67 (P Robo Events 0 0 5 0 0 Chi Events 1 0	Roboti 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1144	2 (P = 0.0 arosc ents 2 1 10 2 2 15 = 3 (P = 0.0 arosc ents 0 8 8	es To 8 4: 1 0 0 0 0 50 9 60); 2 = opic Total 63 42 173 34 312 = 0.93); opic Total 10 63	weight with the second	90.9% 9.1% 00.0% ght M- 3% 4% 0% 3% 0% 3% 0% 4%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07] 0.40 [0.16, 1.03] Odds ratio H, random, 95%CI 3.32 [0.12, 91.60] 0.07 [0.00, 1.25]	Odds M-H, rando O.05 0.2 Favours [Robotic] Odds M-H, rando Odds M-H, rando Otds M-H, rando Otds M-H, rando Odds M-H, rando Odds Odds Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio om, 95%CI
2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0 Fotal for overall effect: Z = 0.0 Fotal fo	00; Chi ² : = 0.67 (P Robo Events 0 0 5 0 0 Color; Chi Z = 1.90 Robo Events 1 0 0	Robotic 4 4 0 0 0 4 = 0.28, = 0.50 ctic Tota 44 42 177 34 296 (P = 0.0)	### Representation of the content of	Event 2 $(P = 0.0)$ 2 $(P = 0.0)$ 2 1 10 2 15 3 $(P = 0.0)$ 2 baroscents 0 8 0	es To 8 4: 1 0 0 0 0 50: 9 60); 2 = 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	weight weight 18.	90.9% 9.1% 00.0% ght M- 3% 4% 0% 3% 0% 3% 0% 4%	Odds ratio 4-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07] 0.40 [0.16, 1.03] Odds ratio H, random, 95%CI 3.32 [0.12, 91.60] 0.07 [0.00, 1.25] Not estimable	Odds M-H, rando O.05 0.2 Favours [Robotic] Odds M-H, rando Odds M-H, rando Otds M-H, rando Otds M-H, rando Odds M-H, rando Odds Odds Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio om, 95%CI
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Total (95% CI) Total events Heterogeneity: Tau² = 0.0 Study or subgroup 2021, Gavrila 2022, Current study 2022, Feng 2021, Gavrila 2022, Current study 2022, Gorgun Total (95% CI) Total events Heterogeneity: Tau² = 0.0 Total (95% CI) Total events Heterogeneity: Tau² = 0.0 Total (95% CI) Total events Heterogeneity: Tau² = 0.0 Total (95% CI) Total (95% CI) Total events Heterogeneity: Tau² = 0.0 Total (95% CI) Total (95% CI) Total (95% CI) Total events Heterogeneity: Tau² = 0.0 Total (95% CI)	00; Chi ² := 0.67 (<i>P</i> Robo Events 0.00; Chi ² := 1.90 Robo Events 1 0 0 0 0 0	Roboti rents 4 0 0 0 0 0 4 4 = 0.28, 0 = 0.50 Otic Tota 44 47 17 30 296 10 10 44 33 44 45	## RT2 10 46 42 174 1144 4f = 1	2 (P = 0.0 arosc ents 2 1 10 2 2 15 = 3 (P = 0.0 arosc ents 0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	es To 8 4: 1 0 0 0 0 50: 9 60); 2 = 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	weight weight with the second weight	90.9% 9.1% 00.0% ght M- 3% 4% 0% 33% 0% %	Odds ratio M-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07] 0.40 [0.16, 1.03] Odds ratio H, random, 95%CI 3.32 [0.12, 91.60] 0.07 [0.00, 1.25] Not estimable Not estimable Not estimable	Odds M-H, rando O.05 0.2 Favours [Robotic] Odds M-H, rando Odds M-H, rando Otds M-H, rando Otds M-H, rando Odds M-H, rando Odds Odds Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio om, 95%CI
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Total (95% CI) Total events Heterogeneity: Tau² = 0.0 Study or subgroup 2021, Gavrila 2022, Current study 2022, Feng 2022, Gorgun Total (95% CI) Total events Heterogeneity: Tau² = 0.0 Total (95% CI) Total events Heterogeneity: Tau² = 0.0 Total (95% CI) Total (95% CI) Total events Heterogeneity: Tau² = 0.0 Total (95% CI) Total (95% CI) Total (95% CI) Total events Heterogeneity: Tau² = 0.0 Total (95% CI)	00; Chi ² := 0.67 (<i>P</i> Robo Events 0.00; Chi 5 0.00; Chi 7 Robo Events 1 0 0 0 0 0 0	Robotic 14 42 174 34 296 10 10 11 11 11 11 11 11 11 11 11 11 11	872 10 46 42 174 1144 df = 1 1 Eve	2 (P = 0.0 aroscents 2 1 10 2 2 15 = 3 (P = 0.0 aroscents 0 8 0 0 5 5	es To 8 4 1 0 0 0 0 50 9 60); 2 = opic Total 63 42 173 34 312 = 0.93); opic Total 10 63 20 42 173	weight and	90.9% 9.1% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%	Odds ratio M-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07] 0.40 [0.16, 1.03] Odds ratio H, random, 95%CI 3.32 [0.12, 91.60] 0.07 [0.00, 1.25] Not estimable Not estimable Not estimable 0.09 [0.00, 1.60]	Odds M-H, rando O.05 0.2 Favours [Robotic] Odds M-H, rando Odds M-H, rando Otds M-H, rando Otds M-H, rando Odds M-H, rando Odds Odds Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio om, 95%CI
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0 Fost for overall effect: Z = 0.0 Study or subgroup 2021, Gavrila 2022, Current study 2022, Feng 2022, Gorgun Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0 Fotal (95% CI) Fotal events Heterogeneity: Tau² = 0.0 Fotal (95% CI) Fotal events Fotal (95% CI) Fotal (95% CI	00; Chi ² := 0.67 (<i>P</i> Robo Events 0.00; Chi ² := 1.90 Robo Events 1 0 0 0 0 0	Robotic 14 42 174 34 296 10 10 11 11 11 11 11 11 11 11 11 11 11	872 10 46 42 174 1144 df = 1 1 Eve	2 (P = 0.0 arosc ents 2 1 10 2 2 15 = 3 (P = 0.0 arosc ents 0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	es To 8 4: 1 0 0 0 0 50: 9 60); 2 = 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	weight weight with the second weight	90.9% 9.1% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%	Odds ratio M-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07] 0.40 [0.16, 1.03] Odds ratio H, random, 95%CI 3.32 [0.12, 91.60] 0.07 [0.00, 1.25] Not estimable Not estimable Not estimable	Odds M-H, rando O.05 0.2 Favours [Robotic] Odds M-H, rando Odds M-H, rando Otds M-H, rando Otds M-H, rando Odds M-H, rando Odds Odds Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio om, 95%CI
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Total (95% CI) Total events Heterogeneity: Tau² = 0.0 Study or subgroup 2021, Gavrila 2022, Current study 2022, Feng 2022, Gorgun Total (95% CI) Total events Heterogeneity: Tau² = 0 Total (95% CI) Total events Total (95% CI) Total events Test for overall effect: Z Study or subgroup 2017, Kamali 2021, Gavrila 2021, Kasai 2022, Current study 2022, Feng 2021, Feng 2021, Feng 2022, Gorgun	00; Chi ² := 0.67 (<i>P</i> Robo Events 0.00; Chi 5 0.00; Chi 7 Robo Events 1 0 0 0 0 0 0	Roboti 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1144	2 (P = 0.0 aroscents 2 1 10 2 2 15 = 3 (P = 0.0 aroscents 0 8 0 0 5 5	es To tal 10	weight weight a second with the second weight a second weight	90.9% 9.1% 00.0% ght M- 33% 4% 0% 33% 0% % White M- 9% 11%	Odds ratio 1-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07] 0.40 [0.16, 1.03] Odds ratio H, random, 95%CI 3.32 [0.12, 91.60] 0.07 [0.00, 1.25] Not estimable Not estimable Not estimable 0.09 [0.00, 1.60] 1.29 [0.32, 5.30]	Odds M-H, rando O.05 0.2 Favours [Robotic] Odds M-H, rando Odds M-H, rando Otds M-H, rando Otds M-H, rando Odds M-H, rando Odds Odds Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio om, 95%CI
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Total (95% CI) Total events Heterogeneity: Tau² = 0.0 Study or subgroup 2021, Gavrila 2022, Current study 2022, Feng 2022, Gorgun Total (95% CI) Total events Heterogeneity: Tau² = 0 Total (95% CI) Total events Heterogeneity: Tau² = 0 Study or subgroup 2021, Gavrila 2021, Kasai 2021, Kasai 20022, Current study 2022, Feng 2022, Gorgun Total (95% CI) Total events Heterogeneity: Tau² = 0 Study or subgroup 2017, Kamali 2021, Kasai 20022, Current study 2022, Feng 2022, Gorgun Total (95% CI)	Events 1	Roboti	1144	2 (P = 0.) 2 arosc ents 2 1 10 2 15 3 (P = 3 (P = 0.) 0 8 0 0 5 4	es To tal 10	weight and	90.9% 9.1% 00.0% ght M- 33% 4% 0% 33% 0% % White M- 9% 11%	Odds ratio M-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07] 0.40 [0.16, 1.03] Odds ratio H, random, 95%CI 3.32 [0.12, 91.60] 0.07 [0.00, 1.25] Not estimable Not estimable Not estimable 0.09 [0.00, 1.60]	Odds M-H, rando O.05 0.2 Favours [Robotic] Odds M-H, rando Odds M-H, rando Otds M-H, rando Otds M-H, rando Odds M-H, rando Odds Odds Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio om, 95%CI
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Total (95% CI) Total events Heterogeneity: Tau² = 0.6 Study or subgroup 2021, Gavrila 2022, Current study 2022, Feng 2022, Gorgun Total (95% CI) Total events Heterogeneity: Tau² = 0.6 Test for overall effect: Z Study or subgroup 2021, Gavrila 2022, Gorgun Total (95% CI) Total events Heterogeneity: Tau² = 0.6 Test for overall effect: Z Study or subgroup 2017, Kamali 2021, Gavrila 2021, Gavrila 2021, Kasai 2022, Current study 2022, Feng 2022, Gorgun Total (95% CI) Total events Total (95% CI) Total events	00; Chi²: = 0.67 (P Robo Events 0 0 5 0 0 0 Events 1 0 0 0 0 5 6	Robotic 4 4 0 0 0 0 4 = 0.28, = 0.50 ctic Tota 4(4 47 177 34 48 177 34 338	## Representation ## Representa	Event 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	es To 8 4 1 1 0 0 0 0 50 9 60); 2 = opic Total 63 42 173 34 312 = 0.93); opic Total 10 63 20 42 173 34 342 342 342	weight weight a second weight	90.9% 9.1% 9.1% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%	Odds ratio 1-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07] 0.40 [0.16, 1.03] Odds ratio H, random, 95%CI 3.32 [0.12, 91.60] 0.07 [0.00, 1.25] Not estimable Not estimable Not estimable 0.09 [0.00, 1.60] 1.29 [0.32, 5.30]	Odds M-H, rando O.05 0.2 Favours [Robotic] Odds M-H, rando Odds M-H, rando Otds M-H, rando Otds M-H, rando Odds M-H, rando Odds Odds Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio om, 95%CI
Study or subgroup 2015, Moghadamyeghan 2017, Kamali 2021, Gavrila 2022, Current study 2022, Feng Total (95% CI) Total events Heterogeneity: Tau² = 0.0 Test for overall effect: Z	00; Chi ² := 0.67 (P Robo Events 0 0 5 0 0 0 Events 1 0 0 0 0 5 1.91; Chi	Robotic 117-3-296 117-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-	## RT2 10 46 42 174 1144 4f = 1	Event 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	es To 8 4 1 1 0 0 0 0 50 9 60); 2 = opic Total 63 42 173 34 312 = 0.93); opic Total 10 63 20 42 173 34 342 342 342	weight weight a second weight	90.9% 9.1% 9.1% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%	Odds ratio 1-H, random, 95%CI 0.78 [0.27, 2.22] 0.30 [0.01, 8.33] Not estimable Not estimable Not estimable 0.71 [0.26, 1.94] Odds ratio H, random, 95%CI 0.26 [0.01, 5.64] 0.33 [0.01, 8.22] 0.48 [0.16, 1.44] 0.19 [0.01, 4.07] 0.40 [0.16, 1.03] Odds ratio H, random, 95%CI 3.32 [0.12, 91.60] 0.07 [0.00, 1.25] Not estimable Not estimable Not estimable 0.09 [0.00, 1.60] 1.29 [0.32, 5.30]	Odds M-H, rando O.05 0.2 Favours [Robotic] Odds M-H, rando Odds M-H, rando Otds M-H, rando Otds M-H, rando Odds M-H, rando Odds Odds Odds	Favours [Laparoscopic] ratio om, 95%CI 1 5 20 Favours [Laparoscopic] ratio om, 95%CI 10 10 Favours [Laparoscopic] ratio om, 95%CI




Figure 1 Forest plots. A: Forest plots of the operation time for robotic vs laparoscopic abdominoperineal resection; B: Forest plots of the intraoperative blood loss for robotic vs laparoscopic abdominoperineal resection; C: Forest plots of postoperative complications for robotic vs laparoscopic abdominoperineal resection; D: Forest plots of postoperative mortality for robotic vs laparoscopic abdominoperineal resection; E: Forest plots of the reoperation rates for robotic vs laparoscopic abdominoperineal resection; F: Forest plots of the rate of conversion to open surgery for robotic vs laparoscopic abdominoperineal resection; G: Forest plots of the length of stay for robotic vs langroscopic abdominoperineal resection: H: Forest plots of the number of lymph nodes harvested for robotic vs langroscopic abdominoperineal resection; I: Forest plots of the circumferential resection margin positive rates for robotic vs laparoscopic abdominoperineal resection.

with APR than with LAR[22]. The overall complication rate after APR in our study was 31%. Our retrospective study and meta-analysis showed that RS was effective in reducing the overall incidence of complications after APR. This result is consistent with that of a previous RCT involving patients undergoing LAR and APR procedures [23]. Postoperative complications not only increase the cost and length of hospital stay but also negatively affect long-term prognosis[24,25]. Gamboa et al [26] found that major complications after proctectomy were associated with shortened overall and recurrence-free survival. Thus, our findings have significant clinical implications, as we provide evidence supporting the benefit of RS in reducing complications after APR.

In addition, the advantages of the RS could theoretically bring benefits in terms of conversion to open surgery. A metaanalysis of 42 studies[21] showed that RS reduced the conversion rate. A recent large RCT[23] showed that robotics was associated with a lower conversion rate. However, in our study, there was no difference in the rate of conversion to open surgery between the RS and LS groups. After meta-analysis, conversion rates between RS and LS groups remained comparable. However, our analysis included a limited number of studies; more high-quality studies are needed to evaluate the effect of robotics on conversion to open surgery in APR. In addition, our meta-analysis showed that RS did not reduce the reoperation rate.

In RC surgery, surgeons focus on the quality of tumor resection. The number of harvested lymph nodes is related to the accuracy of tumor staging and oncologic radicality. In addition, it affects the patient's oncologic prognosis[27]. Being CRM positive, defined as having a minimum distance between the tumor and the CRM of 1 mm or less [28], is associated with tumor recurrence and shorter survival [18]. Studies have reported that being CRM positive leads to a 1- to 5-fold increased risk of local recurrence and a 1- to 4-fold increased risk of distant metastasis[23,29-32]. In traditional LS, surgical instruments need to enter the pelvic cavity in a nearly vertical direction, and their operation in the horizontal direction is limited. In addition, the narrow space in the pelvic cavity can lead to interference between instruments. Lower rectal surgery requires the cooperation of experienced assistants[23]. These factors may affect the quality of LS. RS has better three-dimensional vision and more flexible tools. In addition, the operating arm of the robot can be controlled by the surgeon, which can replace the role of the assistant in LS. These factors allow the robot to perform precise surgical manipulations in a narrow space and improve the quality of tumor specimens[21,23]. Although there was no benefit of RS in terms of the number of lymph nodes harvested, our meta-analysis showed that RS significantly reduced the CRM positive rate. However, the sensitivity analysis showed that the total effect of the CRM positive rate was not robust. More studies are needed to explore the effect of RS on the quality of APR in the future.

Minimally invasive surgery is characterized by a rapid recovery of bowel function and a short hospital stay[19]. Postoperative recovery of gastrointestinal function is an important part of enhanced recovery after gastrointestinal tumor surgery, which has important clinical significance. The time to first flatus and time to first defecation after surgery are key indicators of gastrointestinal dysfunction[33]. Our study showed that although RS, compared to LS, did not shorten the time to first defecation, it reduced the time to first flatus. This is similar to the results of a recent meta-analysis [21] in which the time to first flatus after RC surgery was significantly shorter in the RS group $(2.5 \pm 1.4 \text{ d})$ than in the LS group (2.9 ± 2.0 d). In addition, our retrospective study and meta-analysis observed a significantly shorter hospital stay in the RS group than that in the LS group. This may be related to the faster recovery of intestinal function and fewer incidences of complications.

Regarding safety, some researchers have expressed concerns that RS will lead to longer operation times[3]. However, our retrospective study and meta-analysis suggest that RS does not lead to longer operation times. This is similar to the results of several previous studies [23,34,35]. In addition, we found that intraoperative blood loss was significantly lower in the RS group than that in the LS group. This may be due to the technical advantages of the robotic system providing a better surgical field of view, clearer anatomy, and easier suture manipulation, helping to prevent more bleeding[15,18].

A significant limitation of RS is its high cost[23]. Moghadamyeghaneh et al[15] used the nationwide inpatient sample database from 2009 to 2012 and found that the average total hospitalization cost of robotic APR was 37% higher than that of laparoscopy. Similar to previous studies, in the present study, we found a 17% increase in median hospitalization costs in the RS group compared with that in the LS group. Recently, Gorgun et al[12] reported an increase in direct costs of robotic APR compared with those of laparoscopic APR (26% increase in mean cost and 43% increase in median cost); however, the difference was not significant. The increase in hospitalization costs is an important factor hindering the routine application of RS[12]. Increased complication rates and longer hospital stays are associated with increased treatment costs[11]. Compared with LS, the lower complications and shorter hospital stays observed in the robotic group may be beneficial in reducing the high costs of RS treatment. Furthermore, as the use of RS becomes more widespread and the volume of such procedures increases, the cost of robotic devices will likely decrease over time. In the future, conducting further research to explore the cost-effectiveness of RS compared to that of LS will be important.

Our study had some limitations. First, our study was retrospective and may have been subject to some confounding factors. Therefore, we performed a PSM analysis, and the post-PSM RS and LS groups had similar underlying characteristics. Second, it was difficult to compare the effects of the two surgical techniques on long-term survival because the postoperative follow-up time was too short. However, given the concern about the impact of postoperative complications on survival and the lower incidence of postoperative complications in the RS group compared with that in the LS group, it is necessary to evaluate the long-term efficacy of the two surgical methods. Finally, this study was a single-center study, and all operations were performed by the same surgeon, which was not representative of the skill level of most colorectal surgeons. Therefore, we conducted a meta-analysis of data from other previous studies to further confirm the reliability of the results. To the best of our knowledge, this is the first meta-analysis comparing the short-term efficacy of robotic vs laparoscopic APR.

CONCLUSION

RS is a safe and effective treatment for APR in RC. Although RS is more expensive than LS, RS offers better short-term outcomes including fewer complications, fewer positive CRMs, less blood loss, and a faster postoperative recovery. More high-quality prospective studies are warranted to confirm the benefits of RS in APR.

ACKNOWLEDGEMENTS

We would like to express our gratitude to all those who contributed to the study.

FOOTNOTES

Author contributions: Song L, Xu WQ, Wei ZQ, and Tang G made substantial contributions to conception and design; Xu WQ, Wei ZQ, and Tang G contributed to the acquisition of data, analysis, and interpretation; Song L and Tang G wrote the manuscript; Song L, Xu WQ, Wei ZQ, and Tang G supervised the work and edited the manuscript.

Institutional review board statement: The study was reviewed and approved by the First Affiliated Hospital of Chongqing Medical University Institutional Review Board (Approval No. 2022-K533).

Informed consent statement: Considering that the research was retrospective, the need for patients' informed written consent was waived.



WJGS | https://www.wjgnet.com

Conflict-of-interest statement: All the authors have no conflict of interest related to the manuscript.

Data sharing statement: The original anonymous dataset is available on request from the corresponding author at gangtang2017@163.

STROBE statement: The authors have read the STROBE Statement - checklist of items, and the manuscript was prepared and revised according to the STROBE Statement - checklist of items.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Li Song 0009-0003-3372-5972; Wen-Qiong Xu 0009-0001-7970-7900; Zheng-Qiang Wei 0009-0009-6946-646X; Gang Tang 0000-0002-9830-6221.

S-Editor: Yan JP L-Editor: A P-Editor: Xu ZH

REFERENCES

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-249 [PMID: 33538338 DOI:
- Su WC, Huang CW, Ma CJ, Chen PJ, Tsai HL, Chang TK, Chen YC, Li CC, Yeh YS, Wang JY. Feasibility of robot-assisted surgery in 2 elderly patients with rectal cancer. J Minim Access Surg 2021; 17: 165-174 [PMID: 33723180 DOI: 10.4103/jmas.JMAS 154 19]
- Prete FP, Pezzolla A, Prete F, Testini M, Marzaioli R, Patriti A, Jimenez-Rodriguez RM, Gurrado A, Strippoli GFM. Robotic Versus 3 Laparoscopic Minimally Invasive Surgery for Rectal Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Ann Surg 2018; **267**: 1034-1046 [PMID: 28984644 DOI: 10.1097/SLA.0000000000002523]
- Miles WE. A method of performing abdomino-perineal excision for carcinoma of the rectum and of the terminal portion of the pelvic colon 4 (1908). CA Cancer J Clin 1971; 21: 361-364 [PMID: 5001853 DOI: 10.3322/canjclin.21.6.361]
- Zhang X, Wu Q, Hu T, Gu C, Bi L, Wang Z. Laparoscopic Versus Conventional Open Abdominoperineal Resection for Rectal Cancer: An Updated Systematic Review and Meta-Analysis. J Laparoendosc Adv Surg Tech A 2018; 28: 526-539 [PMID: 29406806 DOI: 10.1089/lap.2017.0593]
- Tang B, Lei X, Ai J, Huang Z, Shi J, Li T. Comparison of robotic and laparoscopic rectal cancer surgery: a meta-analysis of randomized 6 controlled trials. World J Surg Oncol 2021; 19: 38 [PMID: 33536032 DOI: 10.1186/s12957-021-02128-2]
- Wang Y, Liu Y, Han G, Yi B, Zhu S. The severity of postoperative complications after robotic versus laparoscopic surgery for rectal cancer: A 7 systematic review, meta-analysis and meta-regression. PLoS One 2020; 15: e0239909 [PMID: 33002066 DOI: 10.1371/journal.pone.0239909]
- Liu G, Zhang S, Zhang Y, Fu X, Liu X. Robotic Surgery in Rectal Cancer: Potential, Challenges, and Opportunities. Curr Treat Options Oncol 8 2022; **23**: 961-979 [PMID: 35438444 DOI: 10.1007/s11864-022-00984-y]
- Qiu H, Yu D, Ye S, Shan R, Ai J, Shi J. Long-term oncological outcomes in robotic versus laparoscopic approach for rectal cancer: A systematic review and meta-analysis. Int J Surg 2020; 80: 225-230 [PMID: 32251720 DOI: 10.1016/j.ijsu.2020.03.009]
- Feng Q, Tang W, Zhang Z, Wei Y, Ren L, Chang W, Zhu D, Liang F, He G, Xu J. Robotic versus laparoscopic abdominoperineal resections 10 for low rectal cancer: A single-center randomized controlled trial. J Surg Oncol 2022; 126: 1481-1493 [PMID: 36036889 DOI: 10.1002/iso.27076]
- Kasai S, Kagawa H, Shiomi A, Hino H, Manabe S, Yamaoka Y, Kato S, Hanaoka M, Kinugasa Y. Advantages of robotic abdominoperineal 11 resection compared with laparoscopic surgery: a single-center retrospective study. Surg Today 2022; 52: 643-651 [PMID: 34417866 DOI: 10.1007/s00595-021-02359-6
- Gorgun E, Cengiz TB, Ozgur I, Dionigi B, Kalady MF, Steele SR. Outcomes and Cost Analysis of Robotic Versus Laparoscopic 12 Abdominoperineal Resection for Rectal Cancer: A Case-Matched Study. Dis Colon Rectum 2022; 65: 1279-1286 [PMID: 35195554 DOI: 10.1097/DCR.0000000000002394]
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558 [PMID: 12111919 DOI: 13 10.1002/sim.1186]
- 14 Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from: https://onlinelibrary.wiley.com/doi/book/10.1002/9780470712184
- 15 Moghadamyeghaneh Z, Phelan M, Smith BR, Stamos MJ. Outcomes of Open, Laparoscopic, and Robotic Abdominoperineal Resections in Patients With Rectal Cancer. Dis Colon Rectum 2015; **58**: 1123-1129 [PMID: 26544808 DOI: 10.1097/DCR.0000000000000475]
- Kamali D, Reddy A, Imam S, Omar K, Jha A, Jha M. Short-term surgical outcomes and patient quality of life between robotic and 16 laparoscopic extralevator abdominoperineal excision for adenocarcinoma of the rectum. Ann R Coll Surg Engl 2017; 99: 607-613 [PMID: 29022779 DOI: 10.1308/rcsann.2017.0093]
- Gavrila D, Bitere O, Droc G, Lacatus M, Minciuna C, Ilie V, Trandafir B, Herlea V, Tudor S, Vasilescu C. Abdominoperineal Resection for Rectal Cancer: Open, Laparoscopic or Robotic Approach. Chirurgia (Bucur) 2021; 116: 573-582 [PMID: 34749853 DOI: 10.21614/chirurgia.116.5.573]

1289



- Wang X, Cao G, Mao W, Lao W, He C. Robot-assisted versus laparoscopic surgery for rectal cancer: A systematic review and meta-analysis. J Cancer Res Ther 2020; 16: 979-989 [PMID: 33004738 DOI: 10.4103/jcrt.JCRT_533_18]
- 19 Cheong C, Kim NK. Minimally Invasive Surgery for Rectal Cancer: Current Status and Future Perspectives. Indian J Surg Oncol 2017; 8: 591-599 [PMID: 29203993 DOI: 10.1007/s13193-017-0624-7]
- 20 Araujo SE, Seid VE, Klajner S. Robotic surgery for rectal cancer: current immediate clinical and oncological outcomes. World J Gastroenterol 2014; **20**: 14359-14370 [PMID: 25339823 DOI: 10.3748/wjg.v20.i39.14359]
- Safiejko K, Tarkowski R, Koselak M, Juchimiuk M, Tarasik A, Pruc M, Smereka J, Szarpak L. Robotic-Assisted vs. Standard Laparoscopic 21 Surgery for Rectal Cancer Resection: A Systematic Review and Meta-Analysis of 19,731 Patients. Cancers (Basel) 2021; 14 [PMID: 35008344 DOI: 10.3390/cancers14010180]
- Wang XT, Li DG, Li L, Kong FB, Pang LM, Mai W. Meta-analysis of oncological outcome after abdominoperineal resection or low anterior 22 resection for lower rectal cancer. Pathol Oncol Res 2015; 21: 19-27 [PMID: 25430561 DOI: 10.1007/s12253-014-9863-x]
- 23 Feng Q, Yuan W, Li T, Tang B, Jia B, Zhou Y, Zhang W, Zhao R, Zhang C, Cheng L, Zhang X, Liang F, He G, Wei Y, Xu J; REAL Study Group. Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial. Lancet Gastroenterol Hepatol 2022; 7: 991-1004 [PMID: 36087608 DOI: 10.1016/S2468-1253(22)00248-5]
- Tang G, Pi F, Zhang DH, Qiu YH, Wei ZQ. Novel surgical procedure for preventing anastomotic leakage following colorectal cancer surgery: 24 A propensity score matching study. Front Oncol 2022; 12: 1023529 [PMID: 36439499 DOI: 10.3389/fonc.2022.1023529]
- van Kooten RT, Elske van den Akker-Marle M, Putter H, Meershoek-Klein Kranenbarg E, van de Velde CJH, Wouters MWJM, Tollenaar 25 RAEM, Peeters KCMJ. The Impact of Postoperative Complications on Short- and Long-Term Health-Related Quality of Life After Total Mesorectal Excision for Rectal Cancer. Clin Colorectal Cancer 2022; 21: 325-338 [PMID: 36210321 DOI: 10.1016/j.elcc.2022.07.004]
- 26 Gamboa AC, Lee RM, Turgeon MK, Varlamos C, Regenbogen SE, Hrebinko KA, Holder-Murray J, Wiseman JT, Ejaz A, Feng MP, Hawkins AT, Bauer P, Silviera M, Maithel SK, Balch GC. Impact of Postoperative Complications on Oncologic Outcomes After Rectal Cancer Surgery: An Analysis of the US Rectal Cancer Consortium. Ann Surg Oncol 2021; 28: 1712-1721 [PMID: 32968958 DOI: 10.1245/s10434-020-08976-8]
- Tonini V, Birindelli A, Bianchini S, Cervellera M, Bacchi Reggiani ML, Wheeler J, Di Saverio S. Factors affecting the number of lymph nodes retrieved after colo-rectal cancer surgery: A prospective single-centre study. Surgeon 2020; 18: 31-36 [PMID: 31324447 DOI: 10.1016/i.surge.2019.05.0021
- 28 Baik SH, Kim NK, Lee YC, Kim H, Lee KY, Sohn SK, Cho CH. Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer. Ann Surg Oncol 2007; 14: 462-469 [PMID: 17096053 DOI: 10.1245/s10434-006-9171-0]
- Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 2008; 26: 303-29 312 [PMID: 18182672 DOI: 10.1200/JCO.2007.12.7027]
- 30 Birbeck KF, Macklin CP, Tiffin NJ, Parsons W, Dixon MF, Mapstone NP, Abbott CR, Scott N, Finan PJ, Johnston D, Quirke P. Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg 2002; 235: 449-457 [PMID: 11923599 DOI: 10.1097/00000658-200204000-00001]
- Fleshman J, Branda ME, Sargent DJ, Boller AM, George VV, Abbas MA, Peters WR Jr, Maun DC, Chang GJ, Herline A, Fichera A, Mutch 31 MG, Wexner SD, Whiteford MH, Marks J, Birnbaum E, Margolin DA, Larson DW, Marcello PW, Posner MC, Read TE, Monson JRT, Wren SM, Pisters PWT, Nelson H. Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial. Ann Surg 2019; 269: 589-595 [PMID: 30080730 DOI: 10.1097/SLA.0000000000003002]
- Stevenson ARL, Solomon MJ, Brown CSB, Lumley JW, Hewett P, Clouston AD, Gebski VJ, Wilson K, Hague W, Simes J; Australasian Gastro-Intestinal Trials Group (AGITG) ALaCaRT investigators. Disease-free Survival and Local Recurrence After Laparoscopic-assisted Resection or Open Resection for Rectal Cancer: The Australasian Laparoscopic Cancer of the Rectum Randomized Clinical Trial. Ann Surg 2019; 269: 596-602 [PMID: 30247332 DOI: 10.1097/SLA.0000000000003021]
- Tang G, Huang W, Tao J, Wei Z. Prophylactic effects of probiotics or synbiotics on postoperative ileus after gastrointestinal cancer surgery: A 33 meta-analysis of randomized controlled trials. PLoS One 2022; 17: e0264759 [PMID: 35231076 DOI: 10.1371/journal.pone.0264759]
- Baik SH, Ko YT, Kang CM, Lee WJ, Kim NK, Sohn SK, Chi HS, Cho CH. Robotic tumor-specific mesorectal excision of rectal cancer: shortterm outcome of a pilot randomized trial. Surg Endosc 2008; 22: 1601-1608 [PMID: 18270772 DOI: 10.1007/s00464-008-9752-z]
- Tang B, Gao GM, Zou Z, Liu DN, Tang C, Jiang QG, Lei X, Li TY. [Efficacy comparison between robot-assisted and laparoscopic surgery for 35 mid-low rectal cancer: a prospective randomized controlled trial]. Zhonghua Wei Chang Wai Ke Za Zhi 2020; 23: 377-383 [PMID: 32306606 DOI: 10.3760/cma.j.cn.441530-20190401-00135]

1290



Published by Baishideng Publishing Group Inc

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: https://www.f6publishing.com/helpdesk

https://www.wjgnet.com

